Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Disrupting pharmacies is just the start for Hims & Hers.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $21.52, marking a +0.65% move from the previous day.
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers.
Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss Drug
Hims stock is near its all time high and a buy point of 25.74.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.
HIMS: GLP-1 Is Just The Beginning
Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue growth and 270% EBITDA increase, signaling strong financial health and future potential.
